Companies Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics (FULC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Fulcrum Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $6,990,596FY2023
- $1,003,300FY2024
- $3,251,490FY2025
CEO total pay was $3,251,490 in fiscal 2025, up from $1,003,300 in fiscal 2024.
FY2025: salary $650,000 · bonus $0 · stock awards $0 · option awards $2,052,132
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Alex Sapir | $650,000 | $0 | $0 | $2,052,132 | $411,200 | $0 | $138,158 | $3,251,490 |
| President and Chief Executive Officer | ||||||||
| Alan Musso | 478,100 | 0 | 0 | 1,004,910 | 220,000 | 0 | 104,115 | 1,807,125 |
| Chief Financial Officer | ||||||||
| Curtis Oltmans | 472,200 | 0 | 0 | 793,350 | 217,300 | 0 | 0 | 1,482,850 |
| Chief Legal Officer and Head of External Affairs | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Alex Sapir | $3,251,490 | $1,003,300 | $6,990,596 | ↑ +2,248,190 |
| Alan Musso | 1,807,125 | 1,251,760 | 1,879,833 | ↑ +555,365 |
| Curtis Oltmans | 1,482,850 | 1,425,240 | 2,319,661 | ↑ +57,610 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to motivate employees to achieve annual goals based on strategic, financial, and operating performance objectives, while equity grants are intended to create an ownership culture, promote executive retention through time-based vesting, and align executive interests with stockholders by motivating shareholder value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Curtis Oltmans | Option | 3,750 | 12.69 | — |
| Curtis Oltmans | Option | 9,375 | 7.4 | — |
| Curtis Oltmans | Option | 46,875 | 12.59 | — |
| Curtis Oltmans | Option | 47,812 | 2.58 | — |
| Alan Musso | Option | 56,250 | 6.95 | — |
| Curtis Oltmans | Option | 84,375 | 6.95 | — |
| Curtis Oltmans | Option | 182,812 | 4.16 | — |
| Alan Musso | Option | 189,350 | 4.01 | — |
| Alan Musso | Option | 231,562 | 4.16 | — |
| Alex Sapir | Option | 472,875 | 4.16 | — |
| Alex Sapir | Option | 911,400 | 3.27 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kate HavilandIndependent · Board Chair · Audit · Nominating and Corporate Governance | $81,500 | — | $219,406 | — | — | $300,906 |
| Katina DortonIndependent · Audit (Chair) · Compensation | 60,000 | — | 219,406 | — | — | 279,406 |
| James GeraghtyIndependent · Audit · Nominating and Corporate Governance (Chair) | 55,500 | — | 219,406 | — | — | 274,906 |
| Alan EzekowitzIndependent · Science and Technology · Compensation | 53,641 | — | 219,406 | — | — | 273,047 |
| Robert J. GouldNot independent · Science and Technology (Chair) | 50,000 | — | 219,406 | — | — | 269,406 |
| Rachel KingIndependent · Compensation (Chair) | 46,359 | — | 219,406 | — | — | 265,765 |
| Colin HillIndependent · Science and Technology | 45,000 | — | 219,406 | — | — | 264,406 |
| Sonja L. BanksIndependent · Nominating and Corporate Governance | 44,000 | — | 219,406 | — | — | 263,406 |
| Alex C. SapirEmployee director | — | — | — | — | — | 0 |
| Josh LehrerNewly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 5,000 / 4,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $436,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $436,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Fulcrum Therapeutics as a peer
Companies that benchmark against FULC
7 companies name FULC as a compensation peer
The list of companies that name FULC as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Fulcrum Therapeutics, Inc. | 2025 | Alex Sapir | $650,000 | $0 | $2,052,132 | $411,200 | $3,251,490 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-24 | 50,735,617 | 3,026,397 | 27,088 | 94.37% | Passed |
| 2025 | 2025-06-26 | 46,099,800 | 111,967 | 8,304 | 99.76% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-24 | 94.37%a |
| 2025 | 2025-06-26 | 99.76%b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (18 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Alex Sapir. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · page 22. As printed: 3,251,490. View filing ↗
- Section 01, Alan Musso. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 1,807,125. View filing ↗
- Section 01, Curtis Oltmans. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 1,482,850. View filing ↗
- Section 08, Kate Haviland. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 300,906. View filing ↗
- Section 08, Katina Dorton. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 279,406. View filing ↗
- Section 08, James Geraghty. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 274,906. View filing ↗
- Section 08, Alan Ezekowitz. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 273,047. View filing ↗
- Section 08, Robert J. Gould. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 269,406. View filing ↗
- Section 08, Rachel King. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 265,765. View filing ↗
- Section 08, Colin Hill. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 264,406. View filing ↗
- Section 08, Sonja L. Banks. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 263,406. View filing ↗
- Section 08, Alex C. Sapir. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Josh Lehrer. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-25. Item 5.07 · say-on-pay result. As reported: 94.37% (votes for as printed: 50,735,617). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-27. Item 5.07 · say-on-pay result. As reported: 99.76% (votes for as printed: 46,099,800). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 436,000 + equity 0 + all other 0 = 436,000, summed across the director compensation table rows.
- Fulcrum Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Fulcrum Therapeutics, Inc.'s own proxy. As printed: 3,251,490. View filing ↗